You just read:

Daiichi Sankyo Announces ENLIVEN Phase 3 Study of Pexidartinib Met Primary Endpoint in Tenosynovial Giant Cell Tumor

News provided by

Daiichi Sankyo Company, Limited

31 Oct, 2017, 04:00 GMT